26.06.2018 • News

Celonic: Soenke Brunswieck appointed as Vice President Cell & Gene Therapy

Swiss biologics CDMO Celonic has appointed Soenke Brunswieck as VP cell & gene therapy to establish the organization’s new portfolio of CDMO services in the cell and gene therapy domain. "Cell & gene therapy represents a new paradigm in human health, with the potential to resolve unmet medical needs to improve patients’ lives through effective and safe advanced therapeutic medicinal products (ATMPs)", said Dr. Konstantin Matentzoglu, CEO at Celonic. "Celonic appointed Soenke specifically for his extensive expertise with platform technologies and manufacturing of cell & gene therapy products". Soenke has a track record as director of business development and project management at PharmaCell (now Lonza Netherlands). Prior to PharmaCell, he was the director of marketing & sales at CellGenix for over 10 years and was responsible for the creation and successful growth of the global market for GMP-reagents used in cell and gene therapy.

Interview

Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Virtual Event

Perfection Starts in the Tank

High Performance Food Production

On Demand | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.